Nurix Enrolls First Patient in Bexobrutideg CLL Combo Study

Nurix Therapeutics (Nasdaq: NRIX) said on 6 October 2026 that the first patient has been enrolled in the Phase 1b/2 NX-5948-203 study, which pairs its investigational oral BTK degrader bexobrutideg with venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma. The trial, run under the company's global collaboration with Roche, spans two listed study identifiers, NCT07520006 and the NX-5948-203 protocol, and is designed to test safety, tolerability and clinical activity of the combination. No enrollment target, dosing schedule or financial terms were disclosed.

Context — Why a Combination CLL Trial Matters Now

The report positions NX-5948-203 as the fourth clinical program for bexobrutideg. Nurix lists three others: the DAYBreak CLL-201 pivotal single-arm Phase 2 study, NCT07221500, in relapsed or refractory CLL after prior covalent and noncovalent BTK inhibitors plus a BCL2 inhibitor; the DAYBreak CLL-306 randomized Phase 3 trial, NCT07516093, comparing bexobrutideg with pirtobrutinib after a covalent BTK inhibitor; and the NX-5948-301 Phase 1a/1b study, NCT05131022, in relapsed or refractory B-cell malignancies.

That roster is the comparable the report itself supplies. A single asset now sits in a pivotal Phase 2, a randomized Phase 3 and two combination-oriented studies at once, which is unusual breadth for a clinical-stage company whose pipeline is built on targeted protein degradation.

Chief executive Arthur T. Sands framed the rationale directly, saying combination therapies are becoming increasingly important in CLL, particularly in earlier lines of treatment. He added that the company believes bexobrutideg's differentiated mechanism of action, single-agent activity and tolerability make it an attractive combination partner.

What changed to trigger the study now is the maturation of the underlying single-agent data plus the Roche infrastructure. The report says NX-5948-203 is being conducted under the global Nurix-Roche collaboration, the same agreement that covers co-development of bexobrutideg.

The macro backdrop is not addressed in the report, and no index, rate or sector performance figure is provided there. Nurix is a clinical-stage biopharmaceutical company headquartered in Brisbane, California, focused on targeted protein degradation medicines for cancer and autoimmune disease.

Data — What the Trial Numbers Actually Show

Hard figures in the report are limited to trial counts and registry identifiers. Nurix names four bexobrutideg clinical trials, three of them newly referenced in this update and one, NX-5948-301, already running under NCT05131022.

Program	Design	Identifier
NX-5948-203	Phase 1b/2, bexobrutideg + venetoclax	NCT07520006
DAYBreak CLL-201	Pivotal Phase 2, single-arm	NCT07221500
DAYBreak CLL-306	Randomized Phase 3 vs pirtobrutinib	NCT07516093
NX-5948-301	Phase 1a/1b, B-cell malignancies	NCT05131022

The before-and-after here is structural rather than financial. Before this enrollment, bexobrutideg's CLL program rested on single-agent studies. After it, the program includes a combination arm testing bexobrutideg against venetoclax, a BCL2 inhibitor the report describes as a standard of care in CLL.

The report gives no peer comparison, no market capitalization, no cash balance and no enrollment target. It also does not state the number of patients, the dose levels, or the timeline for data readout.

Nurix says data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL. The company also says the strategy includes evaluating bexobrutideg with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts, covering relapsed or refractory and previously untreated patients, with potential expansion into other B-cell malignancies.

Analysis — Where the Risk and the Flow Sit

Second-order effects run through the CLL competitive set. The report names pirtobrutinib as the comparator in DAYBreak CLL-306 and names venetoclax, rituximab and obinutuzumab as combination partners, which places bexobrutideg's development path against established BTK inhibitor and BCL2 inhibitor franchises. Nurix's differentiator, per the report, is mechanism: bexobrutideg is described as an orally bioavailable, brain-penetrant, highly selective small-molecule degrader of BTK, rather than an inhibitor that binds and blocks the enzyme.

The acknowledged limitation is structural. Combination trials carry overlapping toxicity risk that single-agent studies do not, and the report itself flags as a risk factor "the unexpected emergence of adverse events or other undesirable side effects during clinical development." Enrollment of one patient is not efficacy data, and the report provides none.

A second constraint is funding. Nurix lists among its risks whether it "will have adequate resources to fund its obligations under the Nurix-Roche collaboration," language that points to the cost of running four bexobrutideg trials concurrently.

On positioning, the report gives no ownership, short interest or flow data. What it does show is that Nurix's pipeline stretches beyond bexobrutideg: NX-1607, a CBL-B inhibitor, plus clinical-stage IRAK4 degraders with Gilead and STAT6 degraders with Sanofi, alongside preclinical degraders and degrader antibody conjugates with Gilead, Sanofi and Pfizer.

Outlook — What to Watch Next

The report names no dates for data readout, interim analysis or regulatory submission, so the near-term catalysts are the trials themselves. Watch for enrollment updates or initial data from NX-5948-203 in the combination cohort, and for whether the company expands into previously untreated CLL and the anti-CD20 antibody cohorts it has described.

DAYBreak CLL-201 and DAYBreak CLL-306 are the registrational tracks. Progress there matters more to the bexobrutideg thesis than a Phase 1b/2 combination start, because a pivotal Phase 2 and a randomized Phase 3 sit closer to filing decisions.

The report also flags co-commercialization as a live question, listing as a risk whether Nurix and Roche "will be able to successfully co-commercialize bexobrutideg in the United States." Nurix retains certain co-development, co-commercialization and profit-sharing options in the US for multiple candidates under its collaboration agreements.

No price levels, moving averages or yield thresholds appear in the report, so none are cited here.

Frequently Asked Questions

What is bexobrutideg and how does it work?

Bexobrutideg, also called NX-5948, is an investigational oral small molecule that degrades Bruton's tyrosine kinase rather than inhibiting it. Nurix describes it as brain-penetrant and highly selective, and is developing it with Roche across oncology, immunology and neurology. Degraders recruit the cell's own protein-disposal machinery to eliminate a target, a different approach from conventional BTK inhibitors that occupy the enzyme's active site.

What does the NX-5948-203 trial test?

The study evaluates bexobrutideg combined with venetoclax, a BCL2 inhibitor described in the report as a standard of care in CLL. The initial cohort focuses on relapsed or refractory CLL, with potential expansion to previously untreated patients and to anti-CD20 antibodies rituximab and obinutuzumab. The report lists no patient number, dose or timeline.

Why does Nurix run several bexobrutideg trials at once?

The company says data from the combination study are expected to inform registrational strategy across lines of therapy. Running a pivotal Phase 2, a randomized Phase 3 and two combination studies in parallel lets Nurix generate evidence for relapsed and frontline settings simultaneously, though it also raises the funding and toxicity risks the company lists in its own disclosures.

Bottom Line

Nurix has opened a fourth bexobrutideg trial, pushing the Roche-partnered BTK degrader deeper into combination CLL therapy.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.